Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs
On Thursday, genetics-led consumer healthcare company 23andMe Holding Co. (NASDAQ:ME) announced a business restructuring to ...
MM&M27m
How to achieve a successful drug launch in the first year
A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are ...
Hosted on MSN33m
Kering among first to adopt SBTN’s science-based nature targets
While global biopharma company GSK and building materials and solutions company Holcim have adopted the first science-based ...
PipelineReview.com37m
Vesalius Announces Multi-Target Strategic Alliance with GSK to Develop Breakthrough Treatments for People Afflicted with Parkinson’s Disease
Vesalius Will Apply its Proprietary Platform to Identify Novel Intervention Points that GSK may Advance for the Treatment of Patients with Parkinson’s Disease GSK has Licensed a Preclinical Small ...
Macau Business40m
Timor-Leste eliminates lymphatic filariasis as a public health problem
Thomas Breuer, Chief Global Health Officer at GSK, stated, “We congratulate Timor-Leste for this remarkable achievement. The elimination of lymphatic filariasis as a public health problem in ...